

**PENDING CLAIMS**

1. **(Original)** A method for identifying a test agent as reducing apoptosis of a macrophage cell comprising:

- (a) providing:
  - (i) macrophage cells; and
  - (ii) a test agent; and
- (b) contacting said macrophage cells in the presence of said test agent to produce contacted macrophage cells and in the absence of said test agent to produce control cells; and
- (c) detecting reduced activity of Protein Kinase R in said treated cells compared to Protein Kinase R in said control cells, wherein said detecting identifies said test agent as reducing apoptosis of macrophage cells.

2. **(Canceled).**

3. **(Previously Presented)** The method of Claim 1 further comprising, d) identifying said test agent as anti-bacterial.

4. **(Canceled).**

5. **(Canceled).**

6. **(Original)** A method for reducing apoptosis of macrophage cells, comprising:

- (a) providing:
  - (i) macrophage cells; and
  - (ii) an agent that reduces activity of Protein Kinase R; and
- (b) contacting said macrophage cells with said agent under conditions such that said agent reduces activity of said Protein Kinase R.

7. **(Canceled).**

8. **(Original)** The method of Claim 6, wherein said macrophage cells are contacted with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

9. **(Original)** The method of Claim 6, wherein said macrophage cells are contacted with a bacterium.

10. **(Original)** The method of Claim 9, wherein said bacterium is gram-negative.

11. **(Original)** The method of Claim 10, wherein said gram-negative bacterium is one or more of *Yersinia species*, *Salmonella typhimurium*, and *H. influenza*.

12. **(Original)** The method of Claim 9, wherein said bacterium is gram-positive.

13. **(Original)** The method of Claim 12, wherein said gram-positive bacterium is a *B. anthracis*.

14. **(Original)** The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

15. **(Original)** The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a bacterium.

16. **(Previously Presented)** The method of Claim 15, wherein said virus comprises *Influenza virus*.

17. **(Original)** A method of treating a microbial infection in a cell, comprising:

a) providing:

- i) a cell with one or more symptoms of a microbial infection and
  - ii) a formulation comprising a Protein Kinase R inhibitor; and
- b) administering said formulation to said cell under conditions such that said one or more symptoms of a microbial infection are reduced.

18. **(Original)** The method of Claim 17, wherein said cell has a microbial infection associated with one or more symptoms of a viral infection.

19. **(Original)** The method of Claim 17, wherein said microbe is a bacterium.

20. **(Previously Presented)** The method of Claim 19, wherein said bacterium is selected from the group consisting of *Bacillus species*, *Yersinia species*, *Salmonella species*, *Shigella species*, *Streptococcus species* and *Haemophilus species*.

21. **(Previously Presented)** The method of Claim 18, wherein said virus is selected from the group consisting of *Influenzavirus A*, *Influenzavirus B*, and *Influenzavirus C*.

22. **(Original)** The method of Claim 17, wherein said infection is a multiple infection.

23. **(Original)** The method of Claim 22, wherein said multiple infection comprises a bacteria infection and a virus infection.

24. **(Canceled)**.

25. **(Previously Presented)** The method of Claim 17, wherein said cell is in a human patient.

26. **(Previously Presented)** The method of Claim 17, wherein said cell is in a nonhuman animal patient.

26. **(Canceled).**

27. **(Original)** A method of treating a microbial infection in a patient, comprising:

a) providing:

i) a patient with one or more symptoms of a microbial infection and

ii) a formulation comprising a Protein Kinase R inhibitor; and

b) administering said formulation to said patient under conditions such that said one or more symptoms of a microbial infection are reduced.

28. **(Original)** The method of Claim 27, wherein said patient has a microbial infection associated with one or more symptoms of a viral infection.

29. **(Original)** The method of Claim 18, wherein said infection is a bacterial infection.

30. **(Previously Presented)** The method of Claim 29, wherein said bacterium is selected from the group consisting of *Bacillus species*, *Yersinia species*, *Salmonella species*, *Shigella species*, *Streptococcus species* and *Haemophilus species*.

31. **(Previously Presented)** The method of Claim 28, wherein said virus is selected from the group consisting of *Influenzavirus A*, *Influenzavirus B*, and *Influenzavirus C*.

32. **(Original)** The method of Claim 27, wherein said infection is a multiple infection.

33. **(Original)** The method of Claim 32, wherein said multiple infection comprises a bacteria infection and a virus infection.

34. **(Canceled).**